PA-9

• Description:

  PA-9 is a pituitary adenylate cyclase-activating polypeptide (PACAP) type I (PAC1) receptor antagonist. PA-9 dose dependently inhibits PACAP-induced cAMP elevation with an IC50 of 5.6 nM. PA-9 can be used for the research of neuropathic and/or inflammatory pain[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H335

• Target:

  PACAP Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/pa-9.html

• Purity:

  99.73

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)

• Smiles:

  O=C(C(C1)CN(C2=NNC3=C2C=CC=C3)C1=O)NCCC4=CN=CN4

• Molecular Formula:

  C17H18N6O2

• Molecular Weight:

  338.36

• Precautions:

  H315, H319, H335

• References & Citations:

  [1]Takasaki I, et al. In Silico Screening Identified Novel Small-molecule Antagonists of PAC1 Receptor. J Pharmacol Exp Ther. 2018 Apr;365 (1) :1-8.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  1436004-46-4